MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Christine E. Ryan, Lindsey E. Roeker, Matthew S. Davids et al.|Future Oncology|2022

Cited by 35